1Welsh RC,Sauriol L,Zhang Z. Cost-effectiveness of enoxaparin compared with unfractionated heparin in ST elevation myocardial infarction patients undergoing pharmacological reperfusion:a Canadian analysis of the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis in Myocardial Infarction (ExTRACT-TIMI) 25 trial[J].{H}Canadian Journal of Cardiology,2009,(12):e399-e405.
3Marcoff L,Zhang Z,Zhang W. Cost effectiveness of enoxaparin in acute ST-segment elevation myocardial infarction:the ExTRACT-TIMI 25 (Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction 25) study[J].{H}Journal of the America College of Cardiology,2009,(14):1271-1279.
5Iramer C,Aguilar MI,Hoffman-Snyder C. Safety and efficacy of ultrasound-enhanced thrombolysis in the treatment of acute middle cerebral artery infarction:a critically appraised topic[J].{H}NEUROLOGIST,2011,(06):346-351.
7Jarai R,Huber I,Bogaerts I. Plasma N-terminal fragment of the prohormone B-type natriuretic peptide concentrations in relation to time to treatment and Thrombolysis in Myocardial Infarction (TIMI) flow:a substudy of the Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT IV-PCI) trial[J].{H}American Heart Journal,2010,(01):131-140.
9Inagaki I,Nagao M,Oikawa S. Internal medicine and neurological diseases:progress in diagnosis and treatment.Topics:Ⅱ neurological diseases related to diabetes mellitus; 2.Cerebral infarction,coma,hypoglycemia[J].Nihon Naika Gakkai Zasshi,2012,(08):2180-2187.
